The Viral Vectors & Plasmid DNA Manufacturing Market size is expected to be worth around US$ 10.6 billion by 2030, according to a new report by Vision Research Reports.
The global Viral Vectors & Plasmid DNA Manufacturing market size was valued at US$ 3.2 billion in 2020 and is anticipated to grow at a CAGR of 20.8% during forecast period 2021 to 2030.
Get the sample pages of report@ https://www.visionresearchreports.com/report/sample/38494
Growth Factors
Advent of advanced therapies including gene therapy that employs the use of various viral and non-viral vectors has paved a way for the treatment of several heritable and acquired diseases that previously lacked effective treatment modalities. Post the approval of Novartis’s Zolgensma, drug developers have begun considering these new areas of treatment as a sustainable business model. Thus, the speculated accelerating investment is expected to drive the growth.
Current production methods for viral vectors are considered tedious, as they are only applicable for scale-out but not for scale-up. Development of a proprietary CAP-GT technology-based cell suspension system by CEVEC Pharmaceuticals GmbH has effectively addressed the challenge of scaling-up by allowing easy handling and improved efficiency of cells.
Report Coverage
| Report Scope | Details |
| Market Size | USD 10.6 Billion by 2030 |
| Growth Rate | CAGR of 20.8% From 2021 to 2030 |
| Base Year | 2020 |
| Historic Data | 2017 to 2020 |
| Forecast Period | 2021 to 2030 |
| ... |
Read Full Story: https://www.digitaljournal.com/pr/viral-vectors-and-plasmid-dna-manufacturing-market-growth-to-hit-20-8-from-2021-to-2030
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.